| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_15d42f684941d5b0617ca7764ebdff07 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-567
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001134
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-22 |
| filingDate |
2017-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96a15810f5d670c26f65f9758688ce26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c1f602281f42cd14d6600a5ab5ac6da
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a1cb7adefe73226c9bcda31604410098
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6cbac45fdc76db697141aeb63a569ee8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba4567b20bbce64e637ac8a5904710c0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c7e7aceeb455cd3cfa55c5d1f040284 |
| publicationDate |
2017-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2017342144-A1 |
| titleOfInvention |
Engineered anti-tgf-beta antibodies and antigen-binding fragments |
| abstract |
Antibodies or antigen-binding fragments thereof are engineered to bind Transforming Growth Factor-β (TGFβ). TGFβ-isoform selective antibodies or antigen-binding fragments thereof may selectively bind human TGFβ1, compared to human TGFβ2 and human TGFβ3, or may selectively bind human TGFβ3, compared to human TGFβ1 and human TGFβ2. The design of the antibodies or antigen-binding fragments thereof is facilitated by a co-crystal structure of a recombinant Fab fragment of GC1008 bound to TGFβ2 and by another co-crystal structure of the scFv version of GC1008 bound to TGFβ1. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11014980-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11384350-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022157773-A3 |
| priorityDate |
2013-03-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |